Literature DB >> 2924414

Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy.

J E Brush1, G Eisenhofer, M Garty, R Stull, B J Maron, R O Cannon, J A Panza, S E Epstein, D S Goldstein.   

Abstract

We examined the uptake and release of norepinephrine in the cardiac circulation and other regional vascular beds in 11 patients with hypertrophic cardiomyopathy (HCM) and in 10 control subjects during simultaneous infusion of tracer-labeled norepinephrine and isoproterenol. Cardiac neuronal uptake of norepinephrine was assessed by comparing regional removal of tracer-labeled norepinephrine with that of tracer-labeled isoproterenol (which is not a substrate for neuronal uptake) and by the relation between production of dihydroxyphenylglycol (DHPG), an exclusively intraneuronal metabolite of norepinephrine, and regional spillover of norepinephrine. Cardiac extraction of norepinephrine averaged 59 +/- 17% in the patients with HCM, significantly less than in the control subjects (79 +/- 13%, p less than 0.05), whereas cardiac extraction of isoproterenol was similar in the two groups (13 +/- 23% versus 13 +/- 14%), indicating that neuronal uptake of norepinephrine was decreased in the patients with HCM. The cardiac arteriovenous difference in norepinephrine was significantly larger in the patients with HCM than in the control subjects (73 +/- 77 versus 13 +/- 50 pg/ml, p less than 0.05), as was the product of the arteriovenous difference in norepinephrine and coronary blood flow (7.3 +/- 7.3 versus 0.8 +/- 3.0 ng/min, p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2924414     DOI: 10.1161/01.cir.79.4.836

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

Review 1.  Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy.

Authors:  Julian O M Ormerod; Michael P Frenneaux; Mark V Sherrid
Journal:  Nat Rev Cardiol       Date:  2016-07-14       Impact factor: 32.419

2.  Exercise heart rates in patients with hypertrophic cardiomyopathy.

Authors:  Hong-Chang Luo; Veronica L Dimaano; Jackelyn M Kembro; Alex Hilser; David Hurtado-de-Mendoza; Iraklis Pozios; Miguel S Tomas; Hulya Yalcin; Ketty Dolores-Cerna; Wilfredo Mormontoy; Miguel A Aon; Duke Cameron; David A Bluemke; Kerry J Stewart; Stuart D Russell; Jorge G Cordova; Theodore P Abraham; M Roselle Abraham
Journal:  Am J Cardiol       Date:  2015-02-04       Impact factor: 2.778

3.  Myocardial beta adrenoceptors and left ventricular function in hypertrophic cardiomyopathy.

Authors:  L Choudhury; S Guzzetti; D C Lefroy; P Nihoyannopoulos; W J McKenna; C M Oakley; P G Camici
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

4.  Role of intact cardiac nerves and reflex mechanisms in desensitization to catecholamines in conscious dogs.

Authors:  J Nejima; N Uemura; D E Vatner; C J Homcy; T H Hintze; S F Vatner
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

Review 5.  Iodine 123-labeled metaiodobenzylguanidine imaging in heart disease.

Authors:  P Merlet; H Valette; J L Dubois-Randé; K Mardon; F Pouillart; M L Bourachot; A Castaigne; A Syrota
Journal:  J Nucl Cardiol       Date:  1994 Mar-Apr       Impact factor: 5.952

6.  Short term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections.

Authors:  A I Günal; A Işik; H Celiker; O Eren; H Celebi; S Y Günal; C Lüleci
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

7.  Regional distribution and kinetics of [18F]6-flurodopamine as a measure of cardiac sympathetic activity in humans.

Authors:  G Coates; R Chirakal; E L Fallen; G Firnau; E S Garnett; M V Kamath; A Scheffel; C Nahmias
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

8.  Shortening baroreflex delay in hypertrophic cardiomyopathy patients -- an unknown effect of β-blockers.

Authors:  Agnieszka Katarzynska-Szymanska; Romuald Ochotny; Zofia Oko-Sarnowska; Hanna Wachowiak-Baszynska; Tomasz Krauze; Jaroslaw Piskorski; Adrian Gwizdala; Przemyslaw Mitkowski; Przemyslaw Guzik
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

9.  Beta-Blockers in Pediatric Hypertrophic Cardiomyopathies.

Authors:  Ingegerd Östman-Smith
Journal:  Rev Recent Clin Trials       Date:  2014

10.  Hypertrophic cardiomyopathy: a desensitized cardiac beta-adrenergic system in the presence of normal plasma catecholamine concentrations.

Authors:  C Schumacher; H Becker; R Conrads; U Schotten; S Pott; M Kellinghaus; M Sigmund; F Schöndube; C Preusse; H D Schulte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.